1. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The Economic Burden of Non–Influenza-Related Viral Respiratory Tract Infection in the United States. Archives of Internal Medicine. 2003;163(4):487.
2. Heikkinen T, Järvinen A. The common cold. Lancet. 2003;361(9351):51-9.
3. Molinari N-AM, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: Measuring disease burden and costs. Vaccine. 2007;25(27):5086-96.
4. Hopken MW, Piaggio AJ, Pabilonia KL, Pierce J, Anderson T, Abdo Z. Predicting whole genome sequencing success for archived avian influenza virus (Orthomyxoviridae) samples using real-time and droplet PCRs. Journal of Virological Methods. 2020;276:113777.
5. Vogel OA, Manicassamy B. Broadly Protective Strategies Against Influenza Viruses: Universal Vaccines and Therapeutics. Front Microbiol. 2020;11:135-.
6. Gasparini, R., et al., Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part I: Influenza life-cycle and currently available drugs. Journal of preventive medicine and hygiene, 2014. 55(3): p. 69.
7. Wang F, Li K, Shi Z. Phosphorus fertilization and mycorrhizal colonization change silver nanoparticle impacts on maize. Ecotoxicology. 2020;30(1):118-29.
8. Hassanzadeh A, Rahman HS, Markov A, Endjun JJ, Zekiy AO, Chartrand MS, et al. Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities. Stem Cell Res Ther. 2021;12(1):297-.
9. Li TCM, Chan MCW, Lee N. Clinical Implications of Antiviral Resistance in Influenza. Viruses. 2015;7(9):4929-44.
10. Abdollahii, S., et al., Adverse Effects of some of the Most Widely used Metal Nanoparticles on the Reproductive System. Journal of Infertility and Reproductive Biology, 2020. 8(3): p. 22-32.
11. Beheshtkhoo, N., M.A.J. Kouhbanani, and F. sadat Dehghani, Fabrication and Properties of Collagen and Polyurethane Polymeric Nanofibers Using Electrospinning Technique for Tissue Engineering Applications. Journal of Environmental Treatment Techniques, 2019. 7(4): p. 802-807.
12. Blecher K, Nasir A, Friedman A. The growing role of nanotechnology in combating infectious disease. Virulence. 2011;2(5):395-401.
13. Vaculovicova M, Michalek P, Krizkova S, Macka M, Adam V. Nanotechnology-based analytical approaches for detection of viruses. Analytical Methods. 2017;9(16):2375-91.
14. Kwon J-H, Lee D-H, Swayne DE, Noh J-Y, Yuk S-S, Erdene-Ochir T-O, et al. Highly Pathogenic Avian Influenza A(H5N8) Viruses Reintroduced into South Korea by Migratory Waterfowl, 2014-2015. Emerg Infect Dis. 2016;22(3):507-10.
15. Li X, Sun J, Lv X, Wang Y, Li Y, Li M, et al. Novel Reassortant Avian Influenza A(H9N2) Virus Isolate in Migratory Waterfowl in Hubei Province, China. Front Microbiol. 2020;11:220-.
16. Parrish CR, Murcia PR, Holmes EC. Influenza virus reservoirs and intermediate hosts: dogs, horses, and new possibilities for influenza virus exposure of humans. J Virol. 2015;89(6):2990-4.
17. Short KR, Richard M, Verhagen JH, van Riel D, Schrauwen EJA, van den Brand JMA, et al. One health, multiple challenges: The inter-species transmission of influenza A virus. One Health. 2015;1:1-13.
18. Zhang H, Li H, Wang W, Wang Y, Han G-Z, Chen H, et al. A unique feature of swine ANP32A provides susceptibility to avian influenza virus infection in pigs. PLoS Pathog. 2020;16(2):e1008330-e.
19. Byrd-Leotis L, Cummings RD, Steinhauer DA. The Interplay between the Host Receptor and Influenza Virus Hemagglutinin and Neuraminidase. Int J Mol Sci. 2017;18(7):1541.
20. Hussain M, Galvin HD, Haw TY, Nutsford AN, Husain M. Drug resistance in influenza A virus: the epidemiology and management. Infect Drug Resist. 2017;10:121-34.
21. Troeger, C.E., et al., Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. The Lancet Respiratory Medicine, 2019. 7(1): p. 69-89.
22. Li X, Sun J, Lv X, Wang Y, Li Y, Li M, et al. Novel Reassortant Avian Influenza A(H9N2) Virus Isolate in Migratory Waterfowl in Hubei Province, China. Front Microbiol. 2020;11:220-.
23. Bourret V. Avian influenza viruses in pigs: An overview. The Veterinary Journal. 2018;239:7-14.
24. Gagnon A, Acosta E, Hallman S, Bourbeau R, Dillon LY, Ouellette N, et al. Pandemic Paradox: Early Life H2N2 Pandemic Influenza Infection Enhanced Susceptibility to Death during the 2009 H1N1 Pandemic. mBio. 2018;9(1):e02091-17.
25. Henritzi D, Petric PP, Lewis NS, Graaf A, Pessia A, Starick E, et al. Surveillance of European Domestic Pig Populations Identifies an Emerging Reservoir of Potentially Zoonotic Swine Influenza A Viruses. Cell Host & Microbe. 2020;28(4):614-27.e6.
26. Morales KF, Paget J, Spreeuwenberg P. Possible explanations for why some countries were harder hit by the pandemic influenza virus in 2009 - a global mortality impact modeling study. BMC Infect Dis. 2017;17(1):642-.
27. Paget J, Spreeuwenberg P, Charu V, Taylor RJ, Iuliano AD, Bresee J, et al. Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. J Glob Health. 2019;9(2):020421-.
28. Schotsaert M, Ysenbaert T, Smet A, Schepens B, Vanderschaeghe D, Stegalkina S, et al. Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategies. Sci Rep. 2016;6:24402-.
29. Yin R, Tran VH, Zhou X, Zheng J, Kwoh CK. Predicting antigenic variants of H1N1 influenza virus based on epidemics and pandemics using a stacking model. PLoS One. 2018;13(12):e0207777-e.
30. Caini S, Kusznierz G, Garate VV, Wangchuk S, Thapa B, de Paula Júnior FJ, et al. The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century. PLoS One. 2019;14(9):e0222381-e.
31. Laurie KL, Horman W, Carolan LA, Chan KF, Layton D, Bean A, et al. Evidence for Viral Interference and Cross-reactive Protective Immunity Between Influenza B Virus Lineages. The Journal of infectious diseases. 2018;217(4):548-59.
32. Papadimitriou-Olivgeris M, Gkikopoulos N, Wüst M, Ballif A, Simonin V, Maulini M, et al. Predictors of mortality of influenza virus infections in a Swiss Hospital during four influenza seasons: Role of quick sequential organ failure assessment. European Journal of Internal Medicine. 2020;74:86-91.
33. Valesano AL, Fitzsimmons WJ, McCrone JT, Petrie JG, Monto AS, Martin ET, et al. Influenza B Viruses Exhibit Lower Within-Host Diversity than Influenza A Viruses in Human Hosts. J Virol. 2020;94(5):e01710-19.
34. Shaw MW, Xu X, Li Y, Normand S, Ueki RT, Kunimoto GY, et al. Reappearance and Global Spread of Variants of Influenza B/Victoria/2/87 Lineage Viruses in the 2000–2001 and 2001–2002 Seasons. Virology. 2002;303(1):1-8.
35. Rosário-Ferreira N, Preto AJ, Melo R, Moreira IS, Brito RMM. The Central Role of Non-Structural Protein 1 (NS1) in Influenza Biology and Infection. Int J Mol Sci. 2020;21(4):1511.
36. Samji, T., Influenza A: understanding the viral life cycle. The Yale journal of biology and medicine, 2009. 82(4): p. 153.
37. Hause BM, Collin EA, Liu R, Huang B, Sheng Z, Lu W, et al. Characterization of a novel influenza virus in cattle and Swine: proposal for a new genus in the Orthomyxoviridae family. mBio. 2014;5(2):e00031-e14.
38. Hause BM, Ducatez M, Collin EA, Ran Z, Liu R, Sheng Z, et al. Isolation of a novel swine influenza virus from Oklahoma in 2011 which is distantly related to human influenza C viruses. PLoS Pathog. 2013;9(2):e1003176-e.
39. Lowen AC, Steel J. Roles of humidity and temperature in shaping influenza seasonality. J Virol. 2014;88(14):7692-5.
40. Cowling BJ, Jin L, Lau EHY, Liao Q, Wu P, Jiang H, et al. Comparative epidemiology of human infections with avian influenza A H7N9 and H5N1 viruses in China: a population-based study of laboratory-confirmed cases. Lancet. 2013;382(9887):129-37.
41. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DAT. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9(5):291-300.
42. Quirouette C, Younis NP, Reddy MB, Beauchemin CAA. A mathematical model describing the localization and spread of influenza A virus infection within the human respiratory tract. PLoS Comput Biol. 2020;16(4):e1007705-e.
43. Richard M, van den Brand JMA, Bestebroer TM, Lexmond P, de Meulder D, Fouchier RAM, et al. Influenza A viruses are transmitted via the air from the nasal respiratory epithelium of ferrets. Nat Commun. 2020;11(1):766-.
44. Garcia-Mauriño C, Moore-Clingenpeel M, Thomas J, Mertz S, Cohen DM, Ramilo O, et al. Viral Load Dynamics and Clinical Disease Severity in Infants With Respiratory Syncytial Virus Infection. The Journal of infectious diseases. 2019;219(8):1207-15.
45. Miao H, Hollenbaugh JA, Zand MS, Holden-Wiltse J, Mosmann TR, Perelson AS, et al. Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol. 2010;84(13):6687-98.
46. Mitchell H, Levin D, Forrest S, Beauchemin CAA, Tipper J, Knight J, et al. Higher level of replication efficiency of 2009 (H1N1) pandemic influenza virus than those of seasonal and avian strains: kinetics from epithelial cell culture and computational modeling. J Virol. 2011;85(2):1125-35.
47. Paksu MS, Aslan K, Kendirli T, Akyildiz BN, Yener N, Yildizdas RD, et al. Neuroinfluenza: evaluation of seasonal influenza associated severe neurological complications in children (a multicenter study). Child’s Nervous System. 2017;34(2):335-47.
48. Sun Y, Wang Q, Yang G, Lin C, Zhang Y, Yang P. Weight and prognosis for influenza A(H1N1)pdm09 infection during the pandemic period between 2009 and 2011: a systematic review of observational studies with meta-analysis. Infectious Diseases. 2016;48(11-12):813-22.
49. Magee, H. and R.D. Goldman, Viral myositis in children. Canadian Family Physician, 2017. 63(5): p. 365-368.
50. NYewale, V. and D. Dharmapalan, Complications and Prognosis of Influenza. Influenza: Complete Spectrum-II-ECAB, 2012: p. 1.
51. Rowe HM, Meliopoulos VA, Iverson A, Bomme P, Schultz-Cherry S, Rosch JW. Direct interactions with influenza promote bacterial adherence during respiratory infections. Nature microbiology. 2019;4(8):1328-36.
52. van der Sluijs KF, van der Poll T, Lutter R, Juffermans NP, Schultz MJ. Bench-to-bedside review: bacterial pneumonia with influenza - pathogenesis and clinical implications. Crit Care. 2010;14(2):219-.
53. Chen JH, Lam HY, Yip CC, Cheng VC, Chan JF, Leung TH, et al. Evaluation of the molecular Xpert Xpress Flu/RSV assay vs. Alere i Influenza A & B assay for rapid detection of influenza viruses. Diagnostic Microbiology and Infectious Disease. 2018;90(3):177-80.
54. Jokela P, Vuorinen T, Waris M, Manninen R. Performance of the Alere i influenza A&B assay and mariPOC test for the rapid detection of influenza A and B viruses. Journal of Clinical Virology. 2015;70:72-6.
55. Leung NHL, Chu DKW, Shiu EYC, Chan K-H, McDevitt JJ, Hau BJP, et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nature medicine. 2020;26(5):676-80.
56. Relitti N, Saraswati AP, Federico S, Khan T, Brindisi M, Zisterer D, et al. Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials. Current Topics in Medicinal Chemistry. 2020;20(6):433-57.
57. To KK, Lu L, Yip CC, Poon RW, Fung AM, Cheng A, et al. Additional molecular testing of saliva specimens improves the detection of respiratory viruses. Emerg Microbes Infect. 2017;6(6):e49-e.
58. Merckx J, Wali R, Schiller I, Caya C, Gore GC, Chartrand C, et al. Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Infection Compared With Reverse Transcriptase Polymerase Chain Reaction. Annals of Internal Medicine. 2017;167(6):394.
59. Arnulf I, Groos E, Dodet P. Kleine–Levin syndrome: A neuropsychiatric disorder. Revue Neurologique. 2018;174(4):216-27.
60. Bruning AHL, Leeflang MMG, Vos JMBW, Spijker R, de Jong MD, Wolthers KC, et al. Rapid Tests for Influenza, Respiratory Syncytial Virus, and Other Respiratory Viruses: A Systematic Review and Meta-analysis. Clin Infect Dis. 2017;65(6):1026-32.
61. Ryu SW, Lee JH, Kim J, Jang MA, Nam JH, Byoun MS, et al. Comparison of two new generation influenza rapid diagnostic tests with instrument-based digital readout systems for influenza virus detection. British Journal of Biomedical Science. 2016;73(3):115-20.
62. Vos LM, Bruning AHL, Reitsma JB, Schuurman R, Riezebos-Brilman A, Hoepelman AIM, et al. Rapid Molecular Tests for Influenza, Respiratory Syncytial Virus, and Other Respiratory Viruses: A Systematic Review of Diagnostic Accuracy and Clinical Impact Studies. Clin Infect Dis. 2019;69(7):1243-53.
63. Warrell CE, Phyo AP, Win MM, McLean ARD, Watthanaworawit W, Swe MMM, et al. Observational study of adult respiratory infections in primary care clinics in Myanmar: understanding the burden of melioidosis, tuberculosis and other infections not covered by empirical treatment regimes. Trans R Soc Trop Med Hyg. 2021;115(8):914-21.
64. Agoritsas K, Mack K, Bonsu BK, Goodman D, Salamon D, Marcon MJ. Evaluation of the Quidel QuickVue test for detection of influenza A and B viruses in the pediatric emergency medicine setting by use of three specimen collection methods. J Clin Microbiol. 2006;44(7):2638-41.
65. Gavin PJ, Thomson RB. Review of Rapid Diagnostic Tests for Influenza. Clinical and Applied Immunology Reviews. 2004;4(3):151-72.
66. Ginocchio CC, Zhang F, Manji R, Arora S, Bornfreund M, Falk L, et al. Evaluation of multiple test methods for the detection of the novel 2009 influenza A (H1N1) during the New York City outbreak. J Clin Virol. 2009;45(3):191-5.
67. Grijalva CG, Poehling KA, Edwards KM, Weinberg GA, Staat MA, Iwane MK, et al. Accuracy and Interpretation of Rapid Influenza Tests in Children. Pediatrics. 2007;119(1):e6-e11.
68. Hurt AC, Alexander R, Hibbert J, Deed N, Barr IG. Performance of six influenza rapid tests in detecting human influenza in clinical specimens. Journal of Clinical Virology. 2007;39(2):132-5.
69. Mehlmann M, Bonner AB, Williams JV, Dankbar DM, Moore CL, Kuchta RD, et al. Comparison of the MChip to viral culture, reverse transcription-PCR, and the QuickVue influenza A+B test for rapid diagnosis of influenza. J Clin Microbiol. 2007;45(4):1234-7.
70. Organization, W.H., Swine influenza-update 3. 2009.
71. Rashid H, Shafi S, Haworth E, El Bashir H, Ali KA, Memish ZA, et al. Value of rapid testing for influenza among Hajj pilgrims. Travel Medicine and Infectious Disease. 2007;5(5):310-3.
72. Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, et al. Seasonal Influenza in Adults and Children—Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases. 2009;48(8):1003-32.
73. Treanor J. Influenza Vaccine — Outmaneuvering Antigenic Shift and Drift. New England Journal of Medicine. 2004;350(3):218-20.
74. Ren X, Li Y, Liu X, Shen X, Gao W, Li J. Computational Identification of Antigenicity-Associated Sites in the Hemagglutinin Protein of A/H1N1 Seasonal Influenza Virus. PLoS One. 2015;10(5):e0126742-e.
75. Yang H-m, Zhao J, Xue J, Yang Y-l, Zhang G-z. Antigenic variation of LaSota and genotype VII Newcastle disease virus (NDV) and their efficacy against challenge with velogenic NDV. Vaccine. 2017;35(1):27-32.
76. Zost SJ, Wu NC, Hensley SE, Wilson IA. Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens. The Journal of infectious diseases. 2019;219(Suppl_1):S38-S45.
77. de Vries RD, Nieuwkoop NJ, Pronk M, de Bruin E, Leroux-Roels G, Huijskens EGW, et al. Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection. Vaccine. 2017;35(2):238-47.
78. Nickol ME, Kindrachuk J. A year of terror and a century of reflection: perspectives on the great influenza pandemic of 1918-1919. BMC Infect Dis. 2019;19(1):117-.
79. Jagadesh A, Salam AAA, Mudgal PP, Arunkumar G. Influenza virus neuraminidase (NA): a target for antivirals and vaccines. Archives of Virology. 2016;161(8):2087-94.
80. Mousa HA-L. Prevention and Treatment of Influenza, Influenza-Like Illness, and Common Cold by Herbal, Complementary, and Natural Therapies. J Evid Based Complementary Altern Med. 2017;22(1):166-74.
81. Yamayoshi S, Kawaoka Y. Current and future influenza vaccines. Nature Medicine. 2019;25(2):212-20.
82. Kouhbanani, M.A.J., et al., Green synthesis and characterization of spherical structure silver nanoparticles using wheatgrass extract. Journal of Environmental Treatment Techniques, 2019. 7(1): p. 142-149.
83. Jalily PH, Duncan MC, Fedida D, Wang J, Tietjen I. Put a cork in it: Plugging the M2 viral ion channel to sink influenza. Antiviral research. 2020;178:104780-.
84. Rahman M, Hoque SA, Islam MA, Rahman SR. Molecular analysis of amantadine-resistant influenza A (H1N1 pdm09) virus isolated from slum dwellers of Dhaka, Bangladesh. Virus Genes. 2017;53(3):377-85.
85. Wang J, Li F, Ma C. Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses. Biopolymers. 2015;104(4):291-309.
86. Van Poelvoorde LAE, Saelens X, Thomas I, Roosens NH. Next-Generation Sequencing: An Eye-Opener for the Surveillance of Antiviral Resistance in Influenza. Trends in Biotechnology. 2020;38(4):360-7.
87. Adams SE, Lee N, Lugovtsev VY, Kan A, Donnelly RP, Ilyushina NA. Effect of influenza H1N1 neuraminidase V116A and I117V mutations on NA activity and sensitivity to NA inhibitors. Antiviral Research. 2019;169:104539.
88. Choi J-G, Kim YS, Kim JH, Chung H-S. Antiviral activity of ethanol extract of Geranii Herba and its components against influenza viruses via neuraminidase inhibition. Sci Rep. 2019;9(1):12132-.
89. Correia V, Santos LA, Gíria M, Almeida-Santos MM, Rebelo-de-Andrade H. Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs. Journal of Medical Virology. 2014;87(1):45-56.
90. Huang W, Li X, Cheng Y, Tan M, Guo J, Wei H, et al. Characteristics of oseltamivir-resistant influenza A (H1N1) pdm09 virus during the 2013-2014 influenza season in Mainland China. Virol J. 2015;12:96-.
91. Kode SS, Pawar SD, Tare DS, Keng SS, Hurt AC, Mullick J. A novel I117T substitution in neuraminidase of highly pathogenic avian influenza H5N1 virus conferring reduced susceptibility to oseltamivir and zanamivir. Veterinary Microbiology. 2019;235:21-4.
92. Kormuth KA, Lakdawala SS. Emerging antiviral resistance. Nature Microbiology. 2019;5(1):4-5.
93. Lackenby A, Besselaar TG, Daniels RS, Fry A, Gregory V, Gubareva LV, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017. Antiviral research. 2018;157:38-46.
94. Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antiviral Therapy. 2012;17(1 Pt B):159-73.
95. Ginting TE, Shinya K, Kyan Y, Makino A, Matsumoto N, Kaneda S, et al. Amino acid changes in hemagglutinin contribute to the replication of oseltamivir-resistant H1N1 influenza viruses. J Virol. 2012;86(1):121-7.
96. de Jong MD, Thanh TT, Khanh TH, Hien VM, Smith GJD, Chau NV, et al. Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection. New England Journal of Medicine. 2005;353(25):2667-72.
97. Pan Erica S, Diep Binh A, Charlebois Edwin D, Auerswald C, Carleton Heather A, Sensabaugh George F, et al. Population Dynamics of Nasal Strains of Methicillin‐ResistantStaphylococcus aureus—and Their Relation to Community‐Associated Disease Activity. The Journal of Infectious Diseases. 2005;192(5):811-8.
98. Jacobs NT, Onuoha NO, Antia A, Steel J, Antia R, Lowen AC. Incomplete influenza A virus genomes occur frequently but are readily complemented during localized viral spread. Nat Commun. 2019;10(1):3526-.
99. Bassetti M, Castaldo N, Carnelutti A. Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives. Expert Opinion on Pharmacotherapy. 2019;20(14):1711-8.
100. Günther SC, Maier JD, Vetter J, Podvalnyy N, Khanzhin N, Hennet T, et al. Antiviral potential of 3’-sialyllactose- and 6’-sialyllactose-conjugated dendritic polymers against human and avian influenza viruses. Sci Rep. 2020;10(1):768-.
101. Aidoud A, Marlet J, Angoulvant D, Debacq C, Gavazzi G, Fougère B. Influenza vaccination as a novel means of preventing coronary heart disease: Effectiveness in older adults. Vaccine. 2020;38(32):4944-55.
102. Modin, D., et al., Influenza vaccine in heart failure: cumulative number of vaccinations, frequency, timing, and survival: a Danish Nationwide Cohort Study. Circulation, 2019. 139(5): p. 575-586.
103. Sandbulte MR, Spickler AR, Zaabel PK, Roth JA. Optimal Use of Vaccines for Control of Influenza A Virus in Swine. Vaccines (Basel). 2015;3(1):22-73.
104. Wagner A, Weinberger B. Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives. Front Immunol. 2020;11:717-.
105. Gallagher S, Povey R. Determinants of older adults’ intentions to vaccinate against influenza: a theoretical application. Journal of Public Health. 2006;28(2):139-44.
106. Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season. MMWR Recomm Rep. 2018;67(3):1-20.
107. Asavapiriyanont S, Kittikraisak W, Suntarattiwong P, Ditsungnoen D, Kaoiean S, Phadungkiatwatana P, et al. Tolerability of trivalent inactivated influenza vaccine among pregnant women, 2015. BMC Pregnancy Childbirth. 2018;18(1):110-.
108. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. N Engl J Med. 2014;370(23):2211-8.
109. Munoz FM. Safety of influenza vaccines in pregnant women. American Journal of Obstetrics and Gynecology. 2012;207(3):S33-S7.
110. Newsome K, Alverson CJ, Williams J, McIntyre AF, Fine AD, Wasserman C, et al. Outcomes of infants born to women with influenza A(H1N1)pdm09. Birth Defects Res. 2019;111(2):88-95.
111. Nordin JD, Kharbanda EO, Benitez GV, Nichol K, Lipkind H, Naleway A, et al. Maternal Safety of Trivalent Inactivated Influenza Vaccine in Pregnant Women. Obstetrics & Gynecology. 2013;121(3):519-25.
112. Nunes MC, Madhi SA. Influenza vaccination during pregnancy for prevention of influenza confirmed illness in the infants: A systematic review and meta-analysis. Hum Vaccin Immunother. 2018;14(3):758-66.
113. Pasternak B, Svanström H, Mølgaard-Nielsen D, Krause TG, Emborg H-D, Melbye M, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ. 2012;344:e2794-e.
114. Rasmussen SA, Jamieson DJ, Uyeki TM. Effects of influenza on pregnant women and infants. American Journal of Obstetrics and Gynecology. 2012;207(3):S3-S8.
115. Regan AK. The safety of maternal immunization. Hum Vaccin Immunother. 2016;12(12):3132-6.
116. Tapia, M.D., et al., Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. The Lancet infectious diseases, 2016. 16(9): p. 1026-1035.
117. Thompson MG, Kwong JC, Regan AK, Katz MA, Drews SJ, Azziz-Baumgartner E, et al. Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010–2016. Clinical Infectious Diseases. 2018;68(9):1444-53.
118. Vojtek I, Dieussaert I, Doherty TM, Franck V, Hanssens L, Miller J, et al. Maternal immunization: where are we now and how to move forward? Annals of Medicine. 2018;50(3):193-208.
119. Dabrera G, Zhao H, Andrews N, Begum F, Green HK, Ellis J, et al. Effectiveness of seasonal influenza vaccination during pregnancy in preventing influenza infection in infants, England, 2013/14. Eurosurveillance. 2014;19(45).
120. Mølgaard‐Nielsen D, Fischer TK, Krause TG, Hviid A. Effectiveness of maternal immunization with trivalent inactivated influenza vaccine in pregnant women and their infants. Journal of Internal Medicine. 2019;286(4):469-80.
121. Vashishtha VM, Kalra A, Choudhury P. Influenza vaccination in India: Position paper of Indian Academy of Pediatrics, 2013. Indian Pediatrics. 2013;50(9):867-74.
122. Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of Maternal Influenza Immunization in Mothers and Infants. New England Journal of Medicine. 2008;359(15):1555-64.
123. Grohskopf LA, Alyanak E, Broder KR, Blanton LH, Fry AM, Jernigan DB, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season. MMWR Recomm Rep. 2020;69(8):1-24.
124. Lee H, Shim EH, You S. Immunodominance hierarchy of influenza subtype-specific neutralizing antibody response as a hurdle to effectiveness of polyvalent vaccine. Hum Vaccin Immunother. 2018;14(10):2537-9.
125. Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018;8(1):9633-.
126. Samuel, R. and J. Miller, Is the influenza vaccine effective in decreasing infection, hospitalization, pneumonia, and mortality in healthy adults? The Journal of the Oklahoma State Medical Association, 2019. 112(3): p. 86.
127. Valkenburg SA, Leung NHL, Bull MB, Yan L-M, Li APY, Poon LLM, et al. The Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine. Front Immunol. 2018;9:1479-.
128. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2012;12(1):36-44.
129. Gasparini R, Schioppa F, Lattanzi M, Barone M, Casula D, Pellegrini M, et al. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria™) in adult and elderly subjects. International Journal of Clinical Practice. 2009;64(4):432-8.
130. Loeb M, Russell ML, Fonseca K, Webby R, Walter SD. Comparison of multiple estimates of efficacy for influenza vaccine. Vaccine. 2011;30(1):1-4.
131. Petrovsky N. Freeing vaccine adjuvants from dangerous immunological dogma. Expert Review of Vaccines. 2008;7(1):7-10.
132. Petrovsky N, Aguilar JC. Vaccine adjuvants: Current state and future trends. Immunology & Cell Biology. 2004;82(5):488-96.
133. Petrovsky N, Ross TM. Challenges in improving influenza vaccine protection in the elderly. Expert Review of Vaccines. 2011;10(1):7-11.
134. Tetsutani K, Ishii KJ. Adjuvants in influenza vaccines. Vaccine. 2012;30(52):7658-61.
135. Lembo D, Donalisio M, Civra A, Argenziano M, Cavalli R. Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections. Expert Opinion on Drug Delivery. 2017;15(1):93-114.
136. Nimmerjahn F, Dudziak D, Dirmeier U, Hobom G, Riedel A, Schlee M, et al. Active NF-κB signalling is a prerequisite for influenza virus infection. Journal of General Virology. 2004;85(8):2347-56.
137. Portney NG, Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. Analytical and Bioanalytical Chemistry. 2006;384(3):620-30.
138. Mosleh-Shirazi S, Kouhbanani MAJ, Beheshtkhoo N, Kasaee SR, Jangjou A, Izadpanah P, et al. Biosynthesis, simulation, and characterization of Ag/AgFeO2 core–shell nanocomposites for antimicrobial applications. Applied Physics A. 2021;127(11).
139. Nakhaei P, Margiana R, Bokov DO, Abdelbasset WK, Jadidi Kouhbanani MA, Varma RS, et al. Liposomes: Structure, Biomedical Applications, and Stability Parameters With Emphasis on Cholesterol. Front Bioeng Biotechnol. 2021;9:705886-.
140. Beheshtkhoo, N., et al., A review of COVID-19: the main ways of transmission and some prevention solutions, clinical symptoms, more vulnerable human groups, risk factors, diagnosis, and treatment. J Environmental Treat Tech, 2020. 8: p. 884-893.
141. Kouhbanani, M.A.J., et al., Green synthesis of spherical silver nanoparticles using Ducrosia anethifolia aqueous extract and its antibacterial activity. Journal of Environmental Treatment Techniques, 2019. 7(3): p. 461-466.
142. Abe M, Murata K, Kojima A, Ifuku Y, Shimizu M, Ataka T, et al. Quantitative Detection of Protein Using a Top-gate Carbon Nanotube Field Effect Transistor. The Journal of Physical Chemistry C. 2007;111(24):8667-70.
143. Bao P-D, Huang T-Q, Liu X-M, Wu T-Q. Surface-enhanced Raman spectroscopy of insect nuclear polyhedrosis virus. Journal of Raman Spectroscopy. 2001;32(4):227-30.
144. Baur J, Gondran C, Holzinger M, Defrancq E, Perrot H, Cosnier S. Label-Free Femtomolar Detection of Target DNA by Impedimetric DNA Sensor Based on Poly(pyrrole-nitrilotriacetic acid) Film. Analytical Chemistry. 2009;82(3):1066-72.
145. Chiu C-S, Lee H-M, Kuo C-T, Gwo S. Immobilization of DNA-Au nanoparticles on aminosilane-functionalized aluminum nitride epitaxial films for surface acoustic wave sensing. Applied Physics Letters. 2008;93(16):163106.
146. Giraud G, Schulze H, Bachmann TT, Campbell CJ, Mount AR, Ghazal P, et al. Solution state hybridization detection using time-resolved fluorescence anisotropy of quantum dot-DNA bioconjugates. Chemical Physics Letters. 2010;484(4-6):309-14.
147. Lechuga LM, Tamayo J, Álvarez M, Carrascosa LG, Yufera A, Doldán R, et al. A highly sensitive microsystem based on nanomechanical biosensors for genomics applications. Sensors and Actuators B: Chemical. 2006;118(1-2):2-10.
148. Palaniappan A, Goh WH, Tey JN, Wijaya IPM, Moochhala SM, Liedberg B, et al. Aligned carbon nanotubes on quartz substrate for liquid gated biosensing. Biosensors and Bioelectronics. 2010;25(8):1989-93.
149. Star A, Tu E, Niemann J, Gabriel J-CP, Joiner CS, Valcke C. Label-free detection of DNA hybridization using carbon nanotube network field-effect transistors. Proc Natl Acad Sci U S A. 2006;103(4):921-6.
150. Su L-C, Chen R-C, Li Y-C, Chang Y-F, Lee Y-J, Lee C-C, et al. Detection of Prostate-Specific Antigen with a Paired Surface Plasma Wave Biosensor. Analytical Chemistry. 2010;82(9):3714-8.
151. Zhang B, Zhang X, Yan H-h, Xu S-j, Tang D-h, Fu W-l. A novel multi-array immunoassay device for tumor markers based on insert-plug model of piezoelectric immunosensor. Biosensors and Bioelectronics. 2007;23(1):19-25.
152. Zhang J, Lang HP, Huber F, Bietsch A, Grange W, Certa U, et al. Rapid and label-free nanomechanical detection of biomarker transcripts in human RNA. Nature Nanotechnology. 2006;1(3):214-20.
153. Kouhbanani MAJ, Sadeghipour Y, Sarani M, Sefidgar E, Ilkhani S, Amani AM, et al. The inhibitory role of synthesized Nickel oxide nanoparticles against Hep-G2, MCF-7, and HT-29 cell lines: the inhibitory role of NiO NPs against Hep-G2, MCF-7, and HT-29 cell lines. Green Chemistry Letters and Reviews. 2021;14(3):444-54.
154. Nasirmoghadas P, Mousakhani A, Behzad F, Beheshtkhoo N, Hassanzadeh A, Nikoo M, et al. Nanoparticles in cancer immunotherapies: An innovative strategy. Biotechnology Progress. 2020;37(2).
155. Os K, Yv R. Nano Drug Delivery Systems to Overcome Cancer Drug Resistance - A Review. Journal of Nanomedicine & Nanotechnology. 2016;7(3).
156. Sharma A, Kumar Arya D, Dua M, Chhatwal GS, Johri AK. Nano-technology for targeted drug delivery to combat antibiotic resistance. Expert Opinion on Drug Delivery. 2012;9(11):1325-32.
157. Ren J. Research on Green Synthetic Iron Nanoparticles. IOP Conference Series: Materials Science and Engineering. 2019;612(2):022025.
158. Rezapour S, Hosseinzadeh E, Jahangiryan A, Tapeh BEG, Beheshtkhoo N, Kouhbanani MAJ, et al. Flavonoid Kaempferol Inhibits the Proliferation and Survival of Human Leukemia HL60 Cells. Current Drug Therapy. 2021;16(4):354-63.
159. Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK. Peptide Vaccine: Progress and Challenges. Vaccines (Basel). 2014;2(3):515-36.
160. Lin LC-W, Chattopadhyay S, Lin J-C, Hu C-MJ. Advances and Opportunities in Nanoparticle- and Nanomaterial-Based Vaccines against Bacterial Infections. Advanced Healthcare Materials. 2018;7(13):1701395.
161. Nandy A, Basak SC. A Brief Review of Computer-Assisted Approaches to Rational Design of Peptide Vaccines. Int J Mol Sci. 2016;17(5):666.
162. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology. 2006;117(1):78-88.
163. Zepp F. Principles of vaccine design—Lessons from nature. Vaccine. 2010;28:C14-C24.
164. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;12(6):509-17.
165. Tsoras AN, Champion JA. Protein and Peptide Biomaterials for Engineered Subunit Vaccines and Immunotherapeutic Applications. Annual Review of Chemical and Biomolecular Engineering. 2019;10(1):337-59.
166. Akagi T, Baba M, Akashi M. Biodegradable Nanoparticles as Vaccine Adjuvants and Delivery Systems: Regulation of Immune Responses by Nanoparticle-Based Vaccine. Polymers in Nanomedicine: Springer Berlin Heidelberg; 2011. p. 31-64.
167. Amorij J-P, Kersten GFA, Saluja V, Tonnis WF, Hinrichs WLJ, Slütter B, et al. Towards tailored vaccine delivery: Needs, challenges and perspectives. Journal of Controlled Release. 2012;161(2):363-76.
168. Du G, Hathout RM, Nasr M, Nejadnik MR, Tu J, Koning RI, et al. Intradermal vaccination with hollow microneedles: A comparative study of various protein antigen and adjuvant encapsulated nanoparticles. Journal of Controlled Release. 2017;266:109-18.
169. Elamanchili P, Lutsiak CME, Hamdy S, Diwan M, Samuel J. “Pathogen-Mimicking” Nanoparticles for Vaccine Delivery to Dendritic Cells. Journal of Immunotherapy. 2007;30(4):378-95.
170. Irvine DJ, Read BJ. Shaping humoral immunity to vaccines through antigen-displaying nanoparticles. Current opinion in immunology. 2020;65:1-6.
171. Leleux J, Roy K. Micro and Nanoparticle-Based Delivery Systems for Vaccine Immunotherapy: An Immunological and Materials Perspective. Advanced Healthcare Materials. 2012;2(1):72-94.
172. Reddy ST, van der Vlies AJ, Simeoni E, Angeli V, Randolph GJ, O’Neil CP, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotechnology. 2007;25(10):1159-64.
173. Tacken PJ, de Vries IJM, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nature Reviews Immunology. 2007;7(10):790-802.
174. Paulis LE, Mandal S, Kreutz M, Figdor CG. Dendritic cell-based nanovaccines for cancer immunotherapy. Current Opinion in Immunology. 2013;25(3):389-95.
175. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269-81.
176. Bhardwaj P, Bhatia E, Sharma S, Ahamad N, Banerjee R. Advancements in prophylactic and therapeutic nanovaccines. Acta Biomater. 2020;108:1-21.
177. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. NATURAL KILLER CELLS IN ANTIVIRAL DEFENSE: Function and Regulation by Innate Cytokines. Annual Review of Immunology. 1999;17(1):189-220.
178. Schmidt S, Tramsen L, Rais B, Ullrich E, Lehrnbecher T. Natural killer cells as a therapeutic tool for infectious diseases - current status and future perspectives. Oncotarget. 2018;9(29):20891-907.
179. Schultz-Cherry S. Role of NK Cells in Influenza Infection. Current Topics in Microbiology and Immunology: Springer International Publishing; 2014. p. 109-20.
180. Ivory K, Prieto E, Spinks C, Armah CN, Goldson AJ, Dainty JR, et al. Selenium supplementation has beneficial and detrimental effects on immunity to influenza vaccine in older adults. Clin Nutr. 2017;36(2):407-15.
181. Wang F, Chen G, Zhao Y. Biomimetic nanoparticles as universal influenza vaccine. Smart Mater Med. 2020;1:21-3.
182. Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. The Pediatric Infectious Disease Journal. 2003;22(2):164-77.
183. Hurt AC, Chotpitayasunondh T, Cox NJ, Daniels R, Fry AM, Gubareva LV, et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. The Lancet Infectious Diseases. 2012;12(3):240-8.
184. Mishin VP, Patel MC, Chesnokov A, De La Cruz J, Nguyen HT, Lollis L, et al. Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir(1). Emerg Infect Dis. 2019;25(10):1969-72.
185. Hayden F. Developing New Antiviral Agents for Influenza Treatment: What Does the Future Hold? Clinical Infectious Diseases. 2009;48(S1):S3-S13.
186. Watanabe A, Chang SC, Kim Min J, Chu Daniel Ws, Ohashi Y. Long‐Acting Neuraminidase Inhibitor Laninamivir Octanoate versus Oseltamivir for Treatment of Influenza: A Double‐Blind, Randomized, Noninferiority Clinical Trial. Clinical Infectious Diseases. 2010;51(10):1167-75.
187. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002;46(4):977-81.
188. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 2005;49(3):981-6.
189. Malakhov MP, Aschenbrenner LM, Smee DF, Wandersee MK, Sidwell RW, Gubareva LV, et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother. 2006;50(4):1470-9.
190. Shetty AK, Peek LA. Peramivir for the treatment of influenza. Expert Review of Anti-infective Therapy. 2012;10(2):123-43.
191. Zaraket H, Saito R. Japanese Surveillance Systems and Treatment for Influenza. Curr Treat Options Infect Dis. 2016;8(4):311-28.
192. Domnich A, Arata L, Amicizia D, Puig-Barberà J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine. 2017;35(4):513-20.
193. Mastelic Gavillet B, Eberhardt CS, Auderset F, Castellino F, Seubert A, Tregoning JS, et al. MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life. The Journal of Immunology. 2015;194(10):4836-45.
194. Goyal DK, Keshav P, Kaur S. Adjuvanted vaccines driven protection against visceral infection in BALB/c mice by Leishmania donovani. Microbial Pathogenesis. 2021;151:104733.
195. Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotloff KL, et al. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response. JAMA. 2015;314(3):237.
196. Cooper, P.D. and N. Petrovsky, Delta inulin: a novel, immunologically active, stable packing structure comprising β-D-[2→ 1] poly (fructo-furanosyl) α-D-glucose polymers. Glycobiology, 2011. 21(5): p. 595-606.
197. Lobigs M, Pavy M, Hall RA, Lobigs P, Cooper P, Komiya T, et al. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J Gen Virol. 2010;91(Pt 6):1407-17.
198. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03A‐Adjuvanted Influenza A (H1N1) 2009 Vaccine for Adults up to 85 Years of Age. Clinical Infectious Diseases. 2010;51(6):668-77.
199. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O’Hagan DT, et al. Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant. Pediatric Infectious Disease Journal. 2009;28(7):563-71.
200. Dey AK, Burke B, Sun Y, Hartog K, Heeney JL, Montefiori D, et al. Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. Vaccine. 2012;30(17):2749-59.
201. Gasper DJ, Neldner B, Plisch EH, Rustom H, Carrow E, Imai H, et al. Effective Respiratory CD8 T-Cell Immunity to Influenza Virus Induced by Intranasal Carbomer-Lecithin-Adjuvanted Non-replicating Vaccines. PLoS Pathog. 2016;12(12):e1006064-e.
202. Lee W, Kingstad-Bakke B, Paulson B, Larsen A, Overmyer K, Marinaik CB, et al. Carbomer-based adjuvant elicits CD8 T-cell immunity by inducing a distinct metabolic state in cross-presenting dendritic cells. PLoS Pathog. 2021;17(1):e1009168-e.
203. Aricò E, Belardelli F. Interferon-α as Antiviral and Antitumor Vaccine Adjuvants: Mechanisms of Action and Response Signature. Journal of Interferon & Cytokine Research. 2012;32(6):235-47.
204. Davidson S, McCabe TM, Crotta S, Gad HH, Hessel EM, Beinke S, et al. IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment. EMBO Mol Med. 2016;8(9):1099-112.
205. Melendi GA, Coviello S, Bhat N, Zea-Hernandez J, Ferolla FM, Polack FP. Breastfeeding is associated with the production of type I interferon in infants infected with influenza virus. Acta Paediatr. 2010;99(10):1517-21.
206. Redford PS, Mayer-Barber KD, McNab FW, Stavropoulos E, Wack A, Sher A, et al. Influenza A virus impairs control of Mycobacterium tuberculosis coinfection through a type I interferon receptor-dependent pathway. The Journal of infectious diseases. 2014;209(2):270-4.
207. Xia C, Vijayan M, Pritzl CJ, Fuchs SY, McDermott AB, Hahm B. Hemagglutinin of Influenza A Virus Antagonizes Type I Interferon (IFN) Responses by Inducing Degradation of Type I IFN Receptor 1. J Virol. 2015;90(5):2403-17.
208. Ghosh MK, Muller HK, Walker AM. Lactation-Based Maternal Educational Immunity Crosses MHC Class I Barriers and Can Impart Th1 Immunity to Th2-Biased Recipients. J Immunol. 2017;199(5):1729-36.
209. Ghosh MK, Nguyen V, Muller HK, Walker AM. Maternal Milk T Cells Drive Development of Transgenerational Th1 Immunity in Offspring Thymus. J Immunol. 2016;197(6):2290-6.
210. Ma LJ, Walter B, Deguzman A, Muller HK, Walker AM. Trans-epithelial immune cell transfer during suckling modulates delayed-type hypersensitivity in recipients as a function of gender. PLoS One. 2008;3(10):e3562-e.
211. Nelson CS, Pollara J, Kunz EL, Jeffries TL, Jr., Duffy R, Beck C, et al. Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. J Virol. 2016;90(10):4951-65.
212. Wilcox CR, Jones CE. Beyond Passive Immunity: Is There Priming of the Fetal Immune System Following Vaccination in Pregnancy and What Are the Potential Clinical Implications? Front Immunol. 2018;9:1548-.
213. Petryayeva E, Algar WR, Medintz IL. Quantum Dots in Bioanalysis: A Review of Applications across Various Platforms for Fluorescence Spectroscopy and Imaging. Applied Spectroscopy. 2013;67(3):215-52.
214. Yun Z, Zhengtao D, Jiachang Y, Fangqiong T, Qun W. Using cadmium telluride quantum dots as a proton flux sensor and applying to detect H9 avian influenza virus. Analytical Biochemistry. 2007;364(2):122-7.
215. Yang SY, Chieh JJ, Wang WC, Yu CY, Lan CB, Chen JH, et al. Ultra-highly sensitive and wash-free bio-detection of H5N1 virus by immunomagnetic reduction assays. Journal of Virological Methods. 2008;153(2):250-2.
216. Driskell JD, Jones CA, Tompkins SM, Tripp RA. One-step assay for detecting influenza virus using dynamic light scattering and gold nanoparticles. The Analyst. 2011;136(15):3083.
217. Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA. Gold nanoparticles for biology and medicine. Angew Chem Int Ed Engl. 2010;49(19):3280-94.
218. Cui Z-Q, Ren Q, Wei H-P, Chen Z, Deng J-Y, Zhang Z-P, et al. Quantum dot–aptamer nanoprobes for recognizing and labeling influenza A virus particles. Nanoscale. 2011;3(6):2454.
219. Jeon SH, Kayhan B, Ben-Yedidia T, Arnon R. A DNA Aptamer Prevents Influenza Infection by Blocking the Receptor Binding Region of the Viral Hemagglutinin. Journal of Biological Chemistry. 2004;279(46):48410-9.
220. Levy M, Cater SF, Ellington AD. Quantum-Dot Aptamer Beacons for the Detection of Proteins. ChemBioChem. 2005;6(12):2163-6.
221. Wongphatcharachai M, Wang P, Enomoto S, Webby RJ, Gramer MR, Amonsin A, et al. Neutralizing DNA aptamers against swine influenza H3N2 viruses. J Clin Microbiol. 2013;51(1):46-54.
222. Xia Y, Tang Y, Yu X, Wan Y, Chen Y, Lu H, et al. Label-Free Virus Capture and Release by a Microfluidic Device Integrated with Porous Silicon Nanowire Forest. Small. 2017;13(6):10.1002/smll.201603135.
223. Lee D-K, Kang J-H, Kwon J, Lee J-S, Lee S, Woo DH, et al. Nano metamaterials for ultrasensitive Terahertz biosensing. Sci Rep. 2017;7(1):8146-.
224. He L, Özdemir ŞK, Zhu J, Kim W, Yang L. Detecting single viruses and nanoparticles using whispering gallery microlasers. Nature Nanotechnology. 2011;6(7):428-32.
225. Pang Y, Rong Z, Wang J, Xiao R, Wang S. A fluorescent aptasensor for H5N1 influenza virus detection based-on the core–shell nanoparticles metal-enhanced fluorescence (MEF). Biosensors and Bioelectronics. 2015;66:527-32.
226. Kong B, Moon S, Kim Y, Heo P, Jung Y, Yu S-H, et al. Virucidal nano-perforator of viral membrane trapping viral RNAs in the endosome. Nat Commun. 2019;10(1):185-.
227. Kim J, Yeom M, Lee T, Kim H-O, Na W, Kang A, et al. Porous gold nanoparticles for attenuating infectivity of influenza A virus. J Nanobiotechnology. 2020;18(1):54-.
228. Villeret, B., et al., Silver nanoparticles impair retinoic acid-inducible gene I-mediated mitochondrial antiviral immunity by blocking the autophagic flux in lung epithelial cells. ACS nano, 2018. 12(2): p. 1188-1202.
229. Xiang D-x, Chen Q, Pang L, Zheng C-l. Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitro. Journal of Virological Methods. 2011;178(1-2):137-42.
230. Ji H, Yang Z, Jiang W, Geng C, Gong M, Xiao H, et al. Antiviral activity of nano carbon fullerene lipidosome against influenza virus in vitro. Journal of Huazhong University of Science and Technology [Medical Sciences]. 2008;28(3):243-6.
231. Anestopoulos I, Kiousi DE, Klavaris A, Galanis A, Salek K, Euston SR, et al. Surface Active Agents and Their Health-Promoting Properties: Molecules of Multifunctional Significance. Pharmaceutics. 2020;12(7):688.
232. Barkat MA, Harshita, Rizwanullah M, Pottoo FH, Beg S, Akhter S, et al. Therapeutic Nanoemulsion: Concept to Delivery. Current Pharmaceutical Design. 2020;26(11):1145-66.
233. Das D, Sahu P, Chaurasia A, Mishra VK, Kashaw SK. Nanoemulsion: The Emerging Contrivance in the Field of Nanotechnology. Nanoscience &Nanotechnology-Asia. 2018;8(2):146-71.
234. Medeiros ASAd, Torres-Rêgo M, Lacerda AF, Rocha HAO, Egito ESTd, Cornélio AM, et al. Self-Assembled Cationic-Covered Nanoemulsion as A Novel Biocompatible Immunoadjuvant for Antiserum Production Against Tityus serrulatus Scorpion Venom. Pharmaceutics. 2020;12(10):927.
235. Rajpoot P, Pathak K, Bali V. Therapeutic Applications of Nanoemulsion Based Drug Delivery Systems: A Review of Patents in Last Two Decades. Recent Patents on Drug Delivery & Formulation. 2011;5(2):163-72.
236. Cui H, Jiang J, Gu W, Sun C, Wu D, Yang T, et al. Photocatalytic Inactivation Efficiency of Anatase Nano-TiO2 Sol on the H9N2 Avian Influenza Virus. Photochemistry and Photobiology. 2010;86(5):1135-9.
237. Bimbo LM, Denisova OV, Mäkilä E, Kaasalainen M, De Brabander JK, Hirvonen J, et al. Inhibition of Influenza A Virus Infection in Vitro by Saliphenylhalamide-Loaded Porous Silicon Nanoparticles. ACS Nano. 2013;7(8):6884-93.
238. Lauster D, Glanz M, Bardua M, Ludwig K, Hellmund M, Hoffmann U, et al. Multivalent Peptide-Nanoparticle Conjugates for Influenza-Virus Inhibition. Angew Chem Int Ed Engl. 2017;56(21):5931-6.
239. Papp I, Sieben C, Ludwig K, Roskamp M, Böttcher C, Schlecht S, et al. Inhibition of Influenza Virus Infection by Multivalent Sialic-Acid-Functionalized Gold Nanoparticles. Small. 2010;6(24):2900-6.
240. Pillet S, Racine T, Nfon C, Di Lenardo TZ, Babiuk S, Ward BJ, et al. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets. Vaccine. 2015;33(46):6282-9.
241. Budama-Kilinc Y, Cakir-Koc R, Ozdemir B, Kaya Z, Badur S. Production and characterization of a conserved M2e peptide-based specific IgY antibody: evaluation of the diagnostic potential via conjugation with latex nanoparticles. Preparative Biochemistry & Biotechnology. 2018;48(10):930-9.
242. Dhakal S, Lu F, Ghimire S, Renu S, Lakshmanappa YS, Hogshead BT, et al. Corn-derived alpha-D-glucan nanoparticles as adjuvant for intramuscular and intranasal immunization in pigs. Nanomedicine: Nanotechnology, Biology and Medicine. 2019;16:226-35.
243. Dhakal S, Hiremath J, Bondra K, Lakshmanappa YS, Shyu D-L, Ouyang K, et al. Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs. Journal of Controlled Release. 2017;247:194-205.
244. Dhakal S, Goodman J, Bondra K, Lakshmanappa YS, Hiremath J, Shyu D-L, et al. Polyanhydride nanovaccine against swine influenza virus in pigs. Vaccine. 2017;35(8):1124-31.
245. Dhakal S, Renu S, Ghimire S, Shaan Lakshmanappa Y, Hogshead BT, Feliciano-Ruiz N, et al. Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs. Front Immunol. 2018;9:934-.
246. Yamamoto Y, Tamiya S, Shibuya M, Nakase I, Yoshioka Y. Peptides with the multibasic cleavage site of the hemagglutinin from highly pathogenic influenza viruses act as cell-penetrating via binding to heparan sulfate and neuropilins. Biochemical and Biophysical Research Communications. 2019;512(3):453-9.
247. Moon JJ, Suh H, Bershteyn A, Stephan MT, Liu H, Huang B, et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater. 2011;10(3):243-51.
248. Lee T-Y, Kim C-U, Bae E-H, Seo S-H, Jeong DG, Yoon S-W, et al. Outer membrane vesicles harboring modified lipid A moiety augment the efficacy of an influenza vaccine exhibiting reduced endotoxicity in a mouse model. Vaccine. 2017;35(4):586-95.
249. Carroll TD, Jegaskanda S, Matzinger SR, Fritts L, McChesney MB, Kent SJ, et al. A Lipid/DNA Adjuvant-Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge. The Journal of infectious diseases. 2018;218(6):856-67.
250. Han J-A, Kang YJ, Shin C, Ra J-S, Shin H-H, Hong SY, et al. Ferritin protein cage nanoparticles as versatile antigen delivery nanoplatforms for dendritic cell (DC)-based vaccine development. Nanomedicine: Nanotechnology, Biology and Medicine. 2014;10(3):561-9.
251. Babapoor S, Neef T, Mittelholzer C, Girshick T, Garmendia A, Shang H, et al. A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection. Influenza Res Treat. 2011;2011:126794-.
252. Rosenkrands I, Vingsbo-Lundberg C, Bundgaard TJ, Lindenstrøm T, Enouf V, van der Werf S, et al. Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes. Vaccine. 2011;29(37):6283-91.
253. Marasini N, Ghaffar KA, Skwarczynski M, Toth I. Liposomes as a Vaccine Delivery System. Micro and Nanotechnology in Vaccine Development: Elsevier; 2017. p. 221-39.
254. Jazayeri SD, Ideris A, Zakaria Z, Shameli K, Moeini H, Omar AR. Cytotoxicity and immunological responses following oral vaccination of nanoencapsulated avian influenza virus H5 DNA vaccine with green synthesis silver nanoparticles. Journal of Controlled Release. 2012;161(1):116-23.
255. Osminkina LA, Timoshenko VY, Shilovsky IP, Kornilaeva GV, Shevchenko SN, Gongalsky MB, et al. Porous silicon nanoparticles as scavengers of hazardous viruses. Journal of Nanoparticle Research. 2014;16(6).
256. Polidoro BA, Carpenter KE, Collins L, Duke NC, Ellison AM, Ellison JC, et al. The loss of species: mangrove extinction risk and geographic areas of global concern. PLoS One. 2010;5(4):e10095-e.
257. Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert review of vaccines. 2010;9(9):1095-107.